Janux Therapeutics (JANX) Proxy Filing summary

Executive summary

• Supplement updates the non-employee director compensation policy, effective June 13, 2024, with immediate effect.

• Changes include modifications to both cash and equity compensation for non-employee directors.

• All other information in the original proxy statement remains unchanged by this supplement.

Voting matters and shareholder proposals

• No changes to the proposals to be acted upon at the annual meeting; voting procedures remain as previously described.

• Stockholders may change or revoke their vote at any time before the annual meeting.

• The company encourages all stockholders to vote, regardless of attendance or share count.

Board of directors and corporate governance

• Non-employee director compensation policy was comprehensively reviewed and amended, with input from FW Cook.

• The policy now includes both cash retainers and equity awards, with specific amounts for committee service and chair roles.